Ana Garcia-Noblejas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Garcia-Noblejas has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Rafael de la Camara
Hospital de la Princesa, Madrid, Spain
9 shared publications - David Navarro
Microbiology Service, Hospital Clínico Universitario, Instituto de Investigación INCLIVA, Valencia, Spain
5 shared publications - Juan Carlos Hernández-Boluda
Hospital Clínico de Valencia, Valencia, Spain
5 shared publications - Nuria Tormo
Servicio de Microbiología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
5 shared publications Carlos Solano
Hematology and Medical Oncology Service, Hospital Clínico Universitario, Valencia, Spain
4 shared publicationsIsabel Benet
Hematology and Medical Oncology Service, Hospital Clínico Universitario, Valencia, Spain
4 shared publications
Latest Publications
- 24 May 2017
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (8) , 1323-1330
Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)
Guidelines recommend autologous stem cell transplantation (ASCT) consolidation in first complete or partial response after regimens including rituximab (R) and high-dose AraC (HDAC), but its use beyond that response is questioned. We present a retrospective analysis of 268 patients with MCL who received ASCT. With a median follow-up for survival patients of 54 months, progression-free survival and overall survival for the whole series were 38 and 74 months, respectively, and for patients transplanted in first CR 49 and 97 months, respectively. Patients without CR before transplant were analyzed separately, those who achieved CR after transplantation had better PFS (48 vs 0.03 months, p < 0.001) and OS (92 vs 16 months, p < 0.001) than the remaining. In univariate analysis, first CR at transplant (p = 0.01) and prior rituximab (p = 0.02) were the variables associated with PFS. For OS, the same variables resulted significant (p = 0.03 and p < 0.001, respectively). In multivariate analysis, only the status at transplant (first CR) remained significant. This retrospective study concludes that ASCT consolidation in first CR induces high survival rates. In other stages of disease, the need of ASCT as consolidation may be questioned.
- 24 May 2017
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (8) , 1323-1330
Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)
Guidelines recommend autologous stem cell transplantation (ASCT) consolidation in first complete or partial response after regimens including rituximab (R) and high-dose AraC (HDAC), but its use beyond that response is questioned. We present a retrospective analysis of 268 patients with MCL who received ASCT. With a median follow-up for survival patients of 54 months, progression-free survival and overall survival for the whole series were 38 and 74 months, respectively, and for patients transplanted in first CR 49 and 97 months, respectively. Patients without CR before transplant were analyzed separately, those who achieved CR after transplantation had better PFS (48 vs 0.03 months, p < 0.001) and OS (92 vs 16 months, p < 0.001) than the remaining. In univariate analysis, first CR at transplant (p = 0.01) and prior rituximab (p = 0.02) were the variables associated with PFS. For OS, the same variables resulted significant (p = 0.03 and p < 0.001, respectively). In multivariate analysis, only the status at transplant (first CR) remained significant. This retrospective study concludes that ASCT consolidation in first CR induces high survival rates. In other stages of disease, the need of ASCT as consolidation may be questioned.
- 19 March 2015
- Published by Wiley in Journal of Medical Virology
- Vol. 87 (9) , 1601-1607
Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia
The role of Natural killer (NK) cells in the control of cytomegalovirus (CMV) infection in allogeneic stem cell transplant recipients has not been precisely characterized. The current study is aimed at investigating the potential role of NK cells expressing the activating receptor NKG2C in affording protection against the development of CMV DNAemia in patients exhibiting detectable CMV‐specific CD8+ T‐cell responses early following transplantation. A total of 61 nonconsecutive patients were included in the study. Peripheral levels of CD56brightCD16−/low and CD56dimCD16+ NKG2C+ NK cells and CMV pp65/IE‐1‐specific IFN‐γ‐producing CD8+ T‐cells were enumerated by flow cytometry at days +30 and +60 after transplant. Neither the absolute number of NKG2C+ NK cells, nor that of CD56brightCD16−/low and CD56dimCD16+ NKG2C+ NK‐cell subsets at day 30 differed significantly between patients with or without subsequent CMV DNAemia. No significant correlation was found between levels of both NKG2C+ NK‐cell populations and the peak CMV DNA load within subsequent episodes of CMV DNAemia. The data indicate that enumeration of NKG2C+ NK cells early after transplant is unlikely to be helpful in identifying those patients at highest risk of developing CMV DNAemia. Moreover, the data do not support a direct implication of NKG2C+ NK cells in preventing the development of CMV DNAemia. J. Med. Virol. 87:1601–1607, 2015.
- 19 March 2015
- Published by Wiley in Journal of Medical Virology
- Vol. 87 (9) , 1601-1607
Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia
The role of Natural killer (NK) cells in the control of cytomegalovirus (CMV) infection in allogeneic stem cell transplant recipients has not been precisely characterized. The current study is aimed at investigating the potential role of NK cells expressing the activating receptor NKG2C in affording protection against the development of CMV DNAemia in patients exhibiting detectable CMV‐specific CD8+ T‐cell responses early following transplantation. A total of 61 nonconsecutive patients were included in the study. Peripheral levels of CD56brightCD16−/low and CD56dimCD16+ NKG2C+ NK cells and CMV pp65/IE‐1‐specific IFN‐γ‐producing CD8+ T‐cells were enumerated by flow cytometry at days +30 and +60 after transplant. Neither the absolute number of NKG2C+ NK cells, nor that of CD56brightCD16−/low and CD56dimCD16+ NKG2C+ NK‐cell subsets at day 30 differed significantly between patients with or without subsequent CMV DNAemia. No significant correlation was found between levels of both NKG2C+ NK‐cell populations and the peak CMV DNA load within subsequent episodes of CMV DNAemia. The data indicate that enumeration of NKG2C+ NK cells early after transplant is unlikely to be helpful in identifying those patients at highest risk of developing CMV DNAemia. Moreover, the data do not support a direct implication of NKG2C+ NK cells in preventing the development of CMV DNAemia. J. Med. Virol. 87:1601–1607, 2015.
- 30 April 2014
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (9) , 1551-1558
Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience
Patients with mantle cell lymphoma (MCL) have an adverse outcome after relapse. Bendamustine has demonstrated a good efficacy and toxicity profile in previously reported trials. In this study, we present a retrospective analysis of the Spanish experience in relapsed/refractory MCL treated with bendamustine in combination or alone with the objective of knowing the efficacy and toxicity profile of this treatment in our current clinical practice. Fifty eight patients were registered: 67 % male with median age of 71 years, and 2 is the median number of previous lines. The most frequent bendamustine regimen was bendamustine plus rituximab (83 %). The median number of cycles was 5 (range 1–8). The overall response rate was 84 % with 53 % of complete response/unconfirmed complete response (CR/uCR). Median progression-free survival (PFS) was 16 months (95 % confidence interval (CI) 13.3–18.8), and for patients who achieved CR/uCR, it was 33 months (95 % CI 11.1–54.2). Median overall survival (OS) was 30 months (95 % CI 25.6–34.9). For PFS, only blastoid histology and not achieving CR after bendamustine had a significant negative impact on the univariate and multivariate analyses (p < 0.05). Nevertheless, for OS, only an elevated lactate dehydrogenase (LDH) had negative impact on both, univariate and multivariate analyses (p < 0.05). Only one case of treatment-related mortality in a 79-year-old patient with very bad performance status was reported. In 280 cycles, 12 (4 %) hospitalizations for febrile neutropenia were reported. In our population, bendamustine has been a good salvage treatment with a favorable toxicity profile in a non selected and heavily pretreated population of patients with MCL.
- 30 April 2014
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (9) , 1551-1558
Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience
Patients with mantle cell lymphoma (MCL) have an adverse outcome after relapse. Bendamustine has demonstrated a good efficacy and toxicity profile in previously reported trials. In this study, we present a retrospective analysis of the Spanish experience in relapsed/refractory MCL treated with bendamustine in combination or alone with the objective of knowing the efficacy and toxicity profile of this treatment in our current clinical practice. Fifty eight patients were registered: 67 % male with median age of 71 years, and 2 is the median number of previous lines. The most frequent bendamustine regimen was bendamustine plus rituximab (83 %). The median number of cycles was 5 (range 1–8). The overall response rate was 84 % with 53 % of complete response/unconfirmed complete response (CR/uCR). Median progression-free survival (PFS) was 16 months (95 % confidence interval (CI) 13.3–18.8), and for patients who achieved CR/uCR, it was 33 months (95 % CI 11.1–54.2). Median overall survival (OS) was 30 months (95 % CI 25.6–34.9). For PFS, only blastoid histology and not achieving CR after bendamustine had a significant negative impact on the univariate and multivariate analyses (p < 0.05). Nevertheless, for OS, only an elevated lactate dehydrogenase (LDH) had negative impact on both, univariate and multivariate analyses (p < 0.05). Only one case of treatment-related mortality in a 79-year-old patient with very bad performance status was reported. In 280 cycles, 12 (4 %) hospitalizations for febrile neutropenia were reported. In our population, bendamustine has been a good salvage treatment with a favorable toxicity profile in a non selected and heavily pretreated population of patients with MCL.
- 18 June 2013
- Published by Elsevier in Medicina Clinica
- Vol. 140 (12) , 569-570
Remisión espontánea de un linfoma no Hodgkin plasmablástico asociado a metotrexato tras disminución de la dosis del fármaco
- 18 June 2013
- Published by Elsevier in Medicina Clinica
- Vol. 140 (12) , 569-570
Remisión espontánea de un linfoma no Hodgkin plasmablástico asociado a metotrexato tras disminución de la dosis del fármaco
- 8 October 2012
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 39 (12) , 1125-1130
Coexistence of Langerhans cell histiocytosis, Rosai–Dorfman disease and splenic lymphoma with fatal outcome after rapid development of histiocytic sarcoma of the liver
The coexistence of skin‐limited Langerhans cell histiocytosis (LCH) and Rosai–Dorfman disease (RDD) is an exceptional finding. The association of lymphomas and histiocytosis is also infrequent. We report the case of a 68‐year‐old man which presented an exceptional association of cutaneousLCHandRDDand splenic marginal zone lymphoma. He was stable for few years. Suddenly, the patient was admitted into Hematology Department with a remarkable enlargement of spleen and liver without enlargement of lymphadenopathies or skin lesions flare. He died 24 h later despite treatment with systemic chemotherapy combined with prednisone. Pre‐mortem biopsy showed infiltration with histiocytic sarcoma. We think that a transdifferentiation phenomenon could explain our case, although we could not show a clonal relationship between the cutaneous and the liver diseases. We also want to pay attention to the fact that a fast transformation to a more aggressive disease can occur long time after the presentation of the first lesion, a problem that stresses the importance of performing a close and permanent follow‐up of these patients.
- 8 October 2012
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 39 (12) , 1125-1130
Coexistence of Langerhans cell histiocytosis, Rosai–Dorfman disease and splenic lymphoma with fatal outcome after rapid development of histiocytic sarcoma of the liver
The coexistence of skin‐limited Langerhans cell histiocytosis (LCH) and Rosai–Dorfman disease (RDD) is an exceptional finding. The association of lymphomas and histiocytosis is also infrequent. We report the case of a 68‐year‐old man which presented an exceptional association of cutaneousLCHandRDDand splenic marginal zone lymphoma. He was stable for few years. Suddenly, the patient was admitted into Hematology Department with a remarkable enlargement of spleen and liver without enlargement of lymphadenopathies or skin lesions flare. He died 24 h later despite treatment with systemic chemotherapy combined with prednisone. Pre‐mortem biopsy showed infiltration with histiocytic sarcoma. We think that a transdifferentiation phenomenon could explain our case, although we could not show a clonal relationship between the cutaneous and the liver diseases. We also want to pay attention to the fact that a fast transformation to a more aggressive disease can occur long time after the presentation of the first lesion, a problem that stresses the importance of performing a close and permanent follow‐up of these patients.
- 14 December 2011
- Published by Wiley in Journal of Medical Virology
- Vol. 84 (2) , 259-267
Functional profile of cytomegalovirus (CMV)‐specific CD8+ T cells and kinetics of NKG2C+ NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients
Immune mechanisms involved in control of cytomegalovirus (CMV) infection in the allogeneic stem cell transplantation setting have not been fully disclosed. CMV pp65 and IE‐1‐specific CD8+ T cells expressing IFN‐γ, TNF‐α, and CD107a, alone or in combination, and NKG2C+ NK cells were prospectively enumerated during 13 episodes of CMV DNAemia. The expansion of monofunctional and polyfunctional CD8+ T cells was associated with CMV DNAemia clearance. The size and functional diversity of the expanding CD8+ T‐cell population was greater in self‐resolved episodes than in episodes treated with antivirals. These differences were related to the magnitude of expansion of cognate antigen IFN‐γ CD4+ T cells. The resolution of CMV DNAemia was associated frequently with a marked expansion of both CD56dim/CD16+ NK cells and NKG2C+ CD56bright/CD16− NK cells. The data lend support to the role of polyfunctional CD8+ T cells in controlling CMV replication in the allogeneic stem cell transplantation setting, and suggest that NKG2C+ NK cells may be involved critically in the resolution of CMV DNAemia episodes. J. Med. Virol. 84:259–267, 2012.
- 14 December 2011
- Published by Wiley in Journal of Medical Virology
- Vol. 84 (2) , 259-267
Functional profile of cytomegalovirus (CMV)‐specific CD8+ T cells and kinetics of NKG2C+ NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients
Immune mechanisms involved in control of cytomegalovirus (CMV) infection in the allogeneic stem cell transplantation setting have not been fully disclosed. CMV pp65 and IE‐1‐specific CD8+ T cells expressing IFN‐γ, TNF‐α, and CD107a, alone or in combination, and NKG2C+ NK cells were prospectively enumerated during 13 episodes of CMV DNAemia. The expansion of monofunctional and polyfunctional CD8+ T cells was associated with CMV DNAemia clearance. The size and functional diversity of the expanding CD8+ T‐cell population was greater in self‐resolved episodes than in episodes treated with antivirals. These differences were related to the magnitude of expansion of cognate antigen IFN‐γ CD4+ T cells. The resolution of CMV DNAemia was associated frequently with a marked expansion of both CD56dim/CD16+ NK cells and NKG2C+ CD56bright/CD16− NK cells. The data lend support to the role of polyfunctional CD8+ T cells in controlling CMV replication in the allogeneic stem cell transplantation setting, and suggest that NKG2C+ NK cells may be involved critically in the resolution of CMV DNAemia episodes. J. Med. Virol. 84:259–267, 2012.
- 30 September 2011
- Published by Elsevier in Leukemia Research
- Vol. 35 (9) , e143-e144
Pneumocystis jirovecii pneumonia as first manifestation of late relapse angioimmunoblastic T-cell lymphoma
- 30 September 2011
- Published by Elsevier in Leukemia Research
- Vol. 35 (9) , e143-e144
Pneumocystis jirovecii pneumonia as first manifestation of late relapse angioimmunoblastic T-cell lymphoma
- Open Access
- 15 July 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (3) , 313-315
Effect of cytomegalovirus (CMV) serostatus on the incidence and virological features of active CMV infection in allogeneic stem cell transplant recipients.
- 15 July 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (3) , 313-315
Open AccessEffect of cytomegalovirus (CMV) serostatus on the incidence and virological features of active CMV infection in allogeneic stem cell transplant recipients.
- 17 January 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (11) , 1437-1443
Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT
Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-γ CD8+ and CD4+ T cell responses at days +30, +60 and +90 after transplantation in 133 patients, and established cutoff cell levels protecting from CMV DNAemia within the first 120 days after transplantation. No patients showing IFN-γ CD8+ or IFN-γ CD4+ T-cell counts >1.0 and >1.2 cells/μL, respectively, developed a subsequent episode of CMV DNAemia. Initial or recurrent episodes of CMV DNAemia occurred in the face of IFN-γ T-cell levels below defined thresholds. Negative predictive values at day +30 for the IFN-γ CD8+ and CD4+ T-cell markers were 68.1 and 61.8%, respectively. Recipients of grafts from CMV seropositive, related or HLA-matched donors, or receiving non-myeloablative conditioning had nonsignificant tendencies to reach more frequently protective levels of both T-cell subsets at early and late (day +365) times after transplantation. The use of anti-thymocyte globulin and umbilical cord blood transplantation were associated with impaired CMV-specific T-cell reconstitution. CMV-specific IFN-γ CD8+ and CD4+ T-cell recovery occurred irrespective of detectable CMV DNAemia.
- 17 January 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (11) , 1437-1443
Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT
Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-γ CD8+ and CD4+ T cell responses at days +30, +60 and +90 after transplantation in 133 patients, and established cutoff cell levels protecting from CMV DNAemia within the first 120 days after transplantation. No patients showing IFN-γ CD8+ or IFN-γ CD4+ T-cell counts >1.0 and >1.2 cells/μL, respectively, developed a subsequent episode of CMV DNAemia. Initial or recurrent episodes of CMV DNAemia occurred in the face of IFN-γ T-cell levels below defined thresholds. Negative predictive values at day +30 for the IFN-γ CD8+ and CD4+ T-cell markers were 68.1 and 61.8%, respectively. Recipients of grafts from CMV seropositive, related or HLA-matched donors, or receiving non-myeloablative conditioning had nonsignificant tendencies to reach more frequently protective levels of both T-cell subsets at early and late (day +365) times after transplantation. The use of anti-thymocyte globulin and umbilical cord blood transplantation were associated with impaired CMV-specific T-cell reconstitution. CMV-specific IFN-γ CD8+ and CD4+ T-cell recovery occurred irrespective of detectable CMV DNAemia.
- 10 January 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (11) , 1484-1486
Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection
- 10 January 2011
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (11) , 1484-1486
Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection